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Abstract
Background: Activins are growth factors acting on cell growth and differentiation. Activins are expressed in high grade
breast tumors and they display an antiproliferative effect inducing G0/G1 cell cycle arrest in breast cancer cell lines.
Follistatin and follistatin- related gene (FLRG) bind and neutralize activins. In order to establish if these activin binding
proteins are involved in breast tumor progression, the present study evaluated follistatin and FLRG pattern of mRNA
and protein expression in normal human breast tissue and in different breast proliferative diseases.
Methods: Paraffin embedded specimens of normal breast (NB - n = 8); florid hyperplasia without atypia (FH - n = 17);
fibroadenoma (FIB - n = 17); ductal carcinoma in situ (DCIS - n = 10) and infiltrating ductal carcinoma (IDC - n = 15) were
processed for follistatin and FLRG immunohistochemistry and in situ hybridization. The area and intensity of chromogen
epithelial and stromal staining were analyzed semi-quantitatively.
Results: Follistatin and FLRG were expressed both in normal tissue and in all the breast diseases investigated. Follistatin
staining was detected in the epithelial cytoplasm and nucleus in normal, benign and malignant breast tissue, with a
stronger staining intensity in the peri-alveolar stromal cells of FIB at both mRNA and protein levels. Conversely, FLRG
area and intensity of mRNA and protein staining were higher both in the cytoplasm and in the nucleus of IDC epithelial
cells when compared to NB, while no significant changes in the stromal intensity were observed in all the proliferative
diseases analyzed.
Conclusion: The present findings suggest a role for follistatin in breast benign disease, particularly in FIB, where its
expression was increased in stromal cells. The up regulation of FLRG in IDC suggests a role for this protein in the
progression of breast malignancy. As activin displays an anti-proliferative effect in human mammary cells, the present
findings indicate that an increased FST and FLRG expression in breast proliferative diseases might counteract the anti-
proliferative effects of activin in human breast cancer.
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Activins (A, B and AB, composed respectively of two βA
subunits, two βB subunits and one βA and one βB subu-
nit) are pleiotropic secreted polypeptides. They belong to
the transforming growth factor-β (TGF-β) superfamily
and exhibit regulatory roles over important cell cycle
events such as cell proliferation, differentiation, apoptosis
and consequently tumor growth [1]. Previously, we
reported activin/inhibin localization in human breast [2]
and increased expression of dimeric activin A in breast
cancer tissue homogenates [3]. Importantly, we also dem-
onstrated that in postmenopausal women with breast
cancer, activin A levels in serum were increased and sub-
sequently decreased after mastectomy, suggesting that a
major source had been removed [3]. Despite this, activin's
signal transduction components are down-regulated in
high-grade breast cancer at protein level, as well as activin
βB subunit, demonstrating that even though activin A is
abundantly available in breast carcinoma, its transduction
pathway is decreased [4]. Local inhibins are not increased
either [2,4], leading to the question of why activin A is
unable to induce its signaling pathway and, consequently,
perform its biological functions. Additionally, activins
display an antiproliferative effect in human breast cancer
cells by arresting them in the G0/G1 cell cycle phase [5,6],
an effect that may be counteracted by estrogen, since a
crosstalk between activin and estrogen has been demon-
strated [7].
Activins signal through cell-surface receptors that display
predicted serine/threonine kinase activity. Activins bind
selectively to ActRIB and ActRIIA receptors, while ActRIA
and ActRIIB have been demonstrated to bind promiscu-
ously to other TGF-β components [8,9]. The receptor-acti-
vated Smads 2 and 3 bind to the common smad 4,
forming a complex that moves towards the nucleus, where
it can modulate gene expression and promote activins
biological effects [10]. These biological events are inhib-
ited mainly by the glycosylated single-chain proteins, fol-
listatin (FST) and follistatin-related protein, encoded by
follistatin-related gene (FLRG) [10]. Besides activins, FST
also binds and neutralizes other TGF-β growth factors
such as myostatin and bone morphogenetic proteins
(BMPs) 2, 4, 6 and 7 [11-13], while FLRG has been dem-
onstrated to neutralize myostatin [14,15].
Recently, a number of reports showed that the activin/FST
system plays important roles in the progression of malig-
nant diseases by regulating cell proliferation or angiogen-
esis [16]. Coherently with activin's role in breast
carcinogenesis, FST and FLRG have also been associated
with tumorigenesis of different tissues [17-19]. Specifi-
cally in the mammary gland of immunodeficient SCID
mice, FST-expressing R30C tumor displayed increased
angiogenesis but a higher susceptibility to undergo serum
starvation-induced apoptosis and therefore limiting
tumor progression properties [20]. In high grade infiltrat-
ing ductal carcinomas (IDC), FST expression pattern was
not altered, while FLRG expression was increased in the
same tumor. Moreover, FLRG silencing through small
interfering RNA (siRNA) induced significant tumor
growth inhibition, an effect that was reversed upon the
addition of exogenous FLRG [17], demonstrating that
FLRG antagonizes activin effects in neoplastic cells.
In order to determine whether there is an aberrant expres-
sion of FLRG at different stages of tumor progression and
also to determine if FST is involved in human breast
tumor progression, we investigated the expression profile
of activin binding proteins in different human breast pro-
liferative diseases. Specifically, the aim of the present
study was to define the expressional pattern of FST and
FLRG in normal breast (NB) and in different cases of
breast proliferative diseases such as: florid hyperplasia
without atypia (FH), fibroadenoma (FIB), ductal carci-
noma in situ (DCIS) and infiltrating ductal carcinoma
(IDC).
Methods
Subjects
The breast samples used in this study were collected from
67 patients with ages ranging from 29 to 72 years (Table
1) regardless of the menstrual cycle phase or menopausal
status, diagnosed between 2004 and 2006 in the Hermes
Pardini Laboratories Pathology Service (Belo Horizonte,
MG, Brazil). We included cases of normal breast (NB, n =
8), florid hyperplasia without atypia (FH, n = 17),
fibroadenoma (FIB, n = 17), ductal carcinoma in situ,
grades 1, 2 and 3 (DCIS, n = 10) and infiltrating ductal
carcinoma, grades 1, 2 and 3 (IDC, n = 15). Breast lesions
were diagnosed by the pathology service of the same insti-
tution and the study was carried out with the permission
Table 1: Histological characterization of the breast proliferative diseases
Cases Age range Number of cases
Normal breast (NB) 29 - 67 8
Florid hyperplasia without atipia (FH) 32 - 71 17
Fibroadenoma (FIB) 30 - 60 17
Ductal carcinoma in situ (DCIS) 29 - 69 10
Infiltrative ductal carcinoma (IDC) 41 - 72 15Page 2 of 10
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Minas Gerais.
Immunohistochemistry
Immunohistochemistry (IHC) was performed on 5-μm
sections that were mounted on gelatinized slides, depar-
affinized and rehydrated through graded concentrations
of ethanol, followed by endogenous peroxidase blockage
by the use of 3% H2O2 in methanol solution. Then, sec-
tions were washed in PBS and incubated with normal rab-
bit serum for 1 h to block non-specific binding sites. The
sections were incubated with the primary antibodies in
0.1% BSA/PBS at 4°C overnight at a final dilution of
1:200. Primary polyclonal antibodies raised against
human antigens used in the present experiment were: rab-
bit anti-FST kindly donated by Dr. Wylie Vale (Salk Insti-
tute, La Jolla, USA) as previously described [21-23] and
rabbit anti-FLRG kindly donated by Dr Véronique
Maguer-Satta (Centre Léon Bérard, Lyon, France)
[21,22,24,25]. Subsequently, biotinylated secondary anti-
bodies were added to the sections during 30 min followed
by peroxidase streptavidin incubation in ABC reagent
(Vectastain Elite Universal Kit - Vector Laboratories, Burl-
ingame CA, EUA). Diaminobenzidine (DAB - Sigma
Chemicals. CO, St Louis, MO, USA) was successively used
in order to visualize the immunolocalization of the pri-
mary antibodies. Tissue slices were counterstained with
hematoxylin (Sigma Chemicals). Negative control slices
were incubated with normal serum instead of primary
antibodies.
Probe preparation
FST and FLRG in situ hybridization probes [21,22,25]
were prepared according to the procedure previously
described [26] and modified [27]. cDNA obtained from
healthy endometrium was amplified by PCR using 200 ng
of primers for FST, FLRG, and the internal control genes β-
actin and GAPDH, all presented in Table 2. FST, FLRG, β-
actin and GAPDH amplicons were then labelled with the
digoxigenin (Dig), Dig-labelled dUTP (Dig-11-UTP, Boe-
hringer Mannheim, Mannheim, Germany).
In situ hybridization
In situ hybridization (ISH) was performed according to
modifications of the method previously described [26].
Briefly, the sections were dewaxed, rehydrated, fixed in
4% paraformaldehyde (for 15 min) and predigested with
proteinase K (3 mg/ml in Tris-EDTA - Boehringer Man-
nheim) (for 12 min at 37°C). After acetylation in 0.25%
acetic anhydride in triethanolamine, permeabilization
with (0,1 M, pH 7.4) phosphate buffer saline (PBS)/Tri-
ton (X100) and ethanol dehydration, slides were ready to
be hybridized. The sections were incubated with hybridi-
zation solution, which contained approximately 13 ng/ml
DIG-labelled probes in hybridization buffer (30% of
100% deionized formamide - Boehringer Mannheim),
20% 20×SSC, 20% TE, 10% enatured salmon sperm DNA
(10 mg/ml, Boehringer Mannheim), 1% tRNA (100 mg/
ml; Boehringer Mannheim), and 14% H2O. The hybridi-
zation solution was incubated at 100°C for 5 min, cooled
on ice for 10 min and incubated at 42°C overnight. Sub-
sequently, for the immunoperoxidase staining, the sec-
tions were incubated with mouse anti-digoxigenin
antibodies (2 μg/ml; Boehringer Mannheim) in PBS-3%
BSA for 1 h. After washing in PBS/0,1% Tween 20, the sec-
tions were incubated in rabbit anti-mouse antibodies cou-
pled to peroxidase (13 μg/ml; DAKO, Milan, Italy) in PBS
with 3% BSA for 30 min. To enhance staining, sections
were incubated with swine antibodies against rabbit
immunoglobulins coupled to peroxidase (26 μg/ml;
DAKO). The immunoreactivity was visualized by DAB
chromogen. Negative control procedures were performed
to assess the specificity of the ISH signal: 1) omitting Dig-
labeled probe; 2) omitting anti-Dig antibody; 3) omitting
Dig-labeled probe and anti-Dig antibody. Slides were
counterstained with hematoxylin, dehydrated with alco-
hol, cleared with xylene and mounted with a coverslip
before observation.
Semiquantitative scoring
Images were acquired and analyzed on a Carl Zeiss Axio-
plan 2 imaging microscope by AxioCam HR CCD camera
and AxioVision 3.1 software (Carl Zeiss, Göttingen, Ger-
many) by three different researchers blinded to patients.
For both in situ hybridization and immunohistochemis-
try, the intensity of epithelium chromogen staining was
graded semiquantitatively on a scale of 0-3 arbitrary units
with 0 indicating no detectable staining, 1 = weak, 2 =
moderate and 3 = strong. The area with positive staining
was analyzed using the following scale: 0 = no detectable
Table 2: Primers and probes used for the in situ hybridization
Gene Primer sequence Product size
FST 5'-TGCCACCTGAGAAAGGCTAC-3'
5'-ACAGACAGGCTCATCCGACT-3'
201 bp
FLRG 5'-ACCTGAGCGTCATGTACCG-3'
5'-TGTGGCACGAGGAGATGTAG-3'
198 bp
B-actin 5'-GAT CAT TGC CCT CCT GAG C-3
5'-CAC CTT CAC CGT TCC AGT TT-3'
308 bp
GAPDH 5'-ATG GGG AAG GTG AAG GTC GG-3'
5'-TGG TGA AGA CGC CAG TGG AC-3'
300 bpPage 3 of 10
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Statistical analysis
The area and intensity of IHC and ISH staining for FST and
FLRG are presented as medians and ranges, and differ-
ences between groups were assessed by Kruskal-Wallis
analysis of variance followed by Dunn's test for non-para-
metric multiple comparisons.
Results
Clinical samples of the breast proliferative diseases were
classified by the consultant pathologist as indicated in the
Table 1. In order to determine cellular localization and the
expressional profile of FST and FLRG in the normal breast
and in different breast proliferative diseases, the tissue
structures that were analyzed for mRNA and protein stain-
ing were: epithelial cytoplasm, epithelial nuclei and stro-
mal tissue. Tissue localization and staining patterns of FST
mRNA and protein are illustrated in Figure 1, with the cor-
responding semiquantitative analyses depicted in Figure
2. The same is shown for FLRG Figure 3 and Figure 4. FST
and FLRG staining localization and patterning were simi-
lar for mRNA and protein, demonstrating that transcrip-
tion and translation were in accordance, and no
differences between the three diverse grades of DCIS and
IDC analyzed were identified (data not shown).
FST expression and tissue distribution
Less than 10% of the cells were stained by the FST probe
in the NB group, while for the breast proliferative disor-
ders, 10-50% of the cells were positive for the probe stain-
ing. FST protein staining was scored between 10-50% for
all the groups analyzed and no differences in the area of
staining were observed for FST in the different stages of
tumor progression examined (Figure 2A and 2B). In all
groups both epithelial cytoplasm and epithelial nucleus
staining were homogeneously distributed throughout the
epithelial cells, with a moderate to weak staining pattern,
although epithelial nucleus staining was undetected in
some cases at the protein level (Figure 2F). No differences
of FST intensity staining were detected for the epithelial
cytoplasm and epithelial nucleus (Figure 2C and 2F). The
stromal staining was weak or undetectable for all the
groups but FIB (Fig 1E and 1F), which showed an
increased intensity of staining at both mRNA (P = 0.033)
(Figure 2G) and protein (P = 0.032) (Figure 2H) level,
when compared to the NB group. The negative controls of
breast tissue showed no staining (Figure 1K and 1L).
FLRG expression and tissue distribution
FLRG staining was present in NB breast tissue and in all
breast proliferative diseases analyzed. FLRG staining at
mRNA (Figure 4A) and protein (Figure 4B) level was
present in less than 10% of the cells in the NB group and
in 10-50% of the cells in the cases of FH, FIB and DCIS. In
IDC cases, probe and immunostaining was present in
more than 50% of the cells, thus demonstrating a signifi-
cant increase when compared to the NB group (P = 0.015
and P = 0.017, for mRNA an protein staining, respec-
tively). Both epithelial cytoplasm and epithelial nucleus
showed weak to moderate staining for all the groups but
IDC, where the diffusely infiltrated small and irregular
epithelial cells showed strong staining at mRNA and pro-
tein level. Conversely, the stromal cells showed a weak
pattern of staining at mRNA and protein levels (Figure 3A
and 3J). Regarding the pre-neoplastic diseases analyzed,
FLRG intensity in the epithelial cytoplasm and nucleus
were not different from the control group. On the other
hand, FLRG staining intensity was stronger in the epithe-
lial cytoplasm of the IDC at mRNA (Figure 4C, P = 0.007)
and protein (Figure 4F, P = 0.008) levels and in the epithe-
lial nucleus for both mRNA (P = 0.016) and protein (P =
0.037). No statistically significant changes in the stromal
intensity were observed in all the proliferative diseases
analyzed (Figure 4G and 4H).
Discussion
In the present paper we first demonstrated that human
breast proliferative disorders such as FH, FIB and DCIS,
express FST and FLRG and confirmed previous findings
describing FST and FLRG expression in NB and IDC [17].
In the NB and in all the breast proliferative disorders ana-
lyzed, FST and FLRG were localized in the epithelial and
in the stromal cells at mRNA and protein levels. These
expressional patterns are similar to the one we [2,28] and
others [4] previously described for activin in human nor-
mal and pathological breast tissues. Here we also found
an increased expression of FST in stromal cells of FIB com-
pared to NB and FLRG up regulation in IDC.
FIB are benign tumors of the breast typically composed of
stromal and epithelial cells [29] and we previously
reported that activin βA was down regulated in this breast
disease [2]. Taken together, the findings that demonstrate
down regulation of activin βA and up regulation of FST in
FIB suggest that activin anti-proliferative effects may be
weakened, thus favoring the cellular events that lead to
the establishment of the FIB lesion. Additionally, in a
mouse model, Krneta and co-workers (2006) [20] showed
that although FST-expressing R30C tumors displayed
increased angiogenesis, they were highly susceptible to
undergo serum starvation-induced apoptosis, suggesting a
role for FST in limiting tumor progression. Moreover,
despite some controversy about the importance of hor-
monal effects in the development of FIB, some reports
documented increased estradiol levels in the serum of
women carrying FIB lesions [29]. In this connection, FST
mRNA transcripts were decreased in the mammary gland
of rats after ovariectomy, showing that FST expression is
regulated by estrogen in the mammary gland [30].Page 4 of 10
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Follistatin representative microscopic views of: mRNA expression (A, C, E, G, I) as detected by in situ hybridization (ISH); and protein expressio  (B, D, F, H, J) as identified by immunohistochemistry (IHC) for normal breast (NB), flori  hyperplasia (FH),fibroade oma (FIB), ductal carcin ma in situ (DCIS) and invasive ductal carcinom  (IDC)igure 1
Follistatin representative microscopic views of: mRNA expression (A, C, E, G, I) as detected by in situ hybridi-
zation (ISH); and protein expression (B, D, F, H, J) as identified by immunohistochemistry (IHC) for normal 
breast (NB), florid hyperplasia (FH), fibroadenoma (FIB), ductal carcinoma in situ (DCIS) and invasive ductal 
carcinoma (IDC). FST staining was detected in the epithelial cytoplasm (arrow) and nucleus (arrowhead) in the normal, 
benign and malignant breast tissue, with a stronger staining in the FIB peri-alveolar stromal cells. Negative controls were per-
formed omitting anti-Dig antibody; Dig-labelled probe and anti-Dig antibody for ISH (K) and omitting the primary antibody for 
IHC (L). Bar 50 μm.
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FST diagrammatic presentation of semi-quantitative data for normal, benign and malignant breast tissueigure 2
FST diagrammatic presentation of semi-quantitative data for normal, benign and malignant breast tissue. FST 
expression was analyzed by in situ hybridization (A,C,E,G) and immunohistochemistry (B,D,F,H,) in the normal breast (NB), 
florid hyperplasia (FH), fibroadenoma (FIB), ductal carcinoma in situ (DCIS) and infiltrative ductal carcinoma (IDC). FST stro-
mal intensity was stronger in the FIB; *p < 0.05 compared to NB (Kruskal-Wallis followed by Dunn's test).
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FLRG representative microscopic views of:igure 3
FLRG representative microscopic views of: mRNA (A,C,E,G,I) and protein (B,D,F,H,J) expression detected by in situ 
hybridization (ISH); and immunohistochemistry (IHC), respectively, in normal breast (NB), florid hyperplasia (FH), fibroade-
noma (FIB), ductal carcinoma in situ (DCIS) and infiltrative ductal carcinoma (IDC). FLRG staining was detectable in the epi-
thelial cytoplasm (arrow) and nucleus (arrowhead) in all the cases analyzed, with some weak staining detected in the stromal 
cells. K and L: negative controls for ISH and IHC respectively. Bar 50 μm.
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FLRG diagrammatic presentation of semi-quantitative data for normal, benign and malignant breast tissueigure 4
FLRG diagrammatic presentation of semi-quantitative data for normal, benign and malignant breast tissue. 
FLRG expression was analyzed by in situ hybridization (A,C,E,G) and immunohistochemistry (B,D,F,H,) in normal breast 
(NB), florid hyperplasia (FH), fibroadenoma (FIB), ductal carcinoma in situ (DCIS) and infiltrative ductal carcinoma (IDC). 
FLRG area of staining was augmented in the IDC, correspondingly, epithelial cytoplasm and nuclear staining was stronger in the 
IDC; *p < 0.05 compared to NB (Kruskal-Wallis followed by Dunn's test).
BMC Cancer 2009, 9:320 http://www.biomedcentral.com/1471-2407/9/320Regarding FLRG, in the present study, we found that its
expression was increased in IDC at protein level as previ-
ously reported [17] and that such increased expression
was also present at mRNA level, implying that the tumor
itself is the source of increased FLRG protein expression.
Concerning activin's role in breast cancer, previously we
reported an increased transcript profile of activin βA sub-
unit and an augmented activin A concentration in
homogenates of breast carcinoma [3]. On the other hand,
in high grade breast cancer, an impairment of the activin
signal transduction system has been linked to oncogenic
progression, since a reduced expression of activin βB and
its receptors, as much as alterations of smad signaling
have been characterized [4]. All in all, together with the
findings that FLRG contributes to tumor cell proliferation
through antagonizing activin effects [17], we assume that
the increased activin A expression reported in breast carci-
noma is counteracted by an increased FLRG expression
that prevents activin from binding its receptors and thus
reducing smad signaling and activin anti-proliferative
effects. Additionally, we also analyzed FLRG pattern of
expression in pre-neoplastic diseases and in DCIS, a lesion
where cancer cells do not infiltrate the adjacent stromal
tissue and which has been pointed to be a precursor of
IDC [31]. FLRG was only over-expressed in the IDC, sug-
gesting that FLRG is strongly correlated with tumor pro-
gression and breast malignancy.
As for the cellular localization, the typical nuclear staining
of FLRG already described in other cell types [32] was
present in the normal and pathologic mammary glands
evaluated here. We also observed FLRG staining in the
cytoplasm, which recapitulates in vivo observations in
human endometrium [21,25]. In the current study, FST
staining was stronger in the cytoplasm, suggesting that the
localization pattern of this protein in mammary gland
epithelial cells is the same already described for other tis-
sues [22,33]. Yet, we also noted nuclear staining of FST,
which is rather atypical but has been described before in
spermatogenic cells [34].
It is interesting to note that FST expression was increased
in the stromal cells of FIB, while FLRG was up regulated in
IDC, indicating that the two activin binding proteins may
play diverse roles in tumor progression. Although their
overall gene structure is quite similar, FST and FLRG seem
to regulate activin pathway in different ways [35]. Indeed,
in human liver tumor specimens, FST expression was
increased in about 60% while FLRG transcript profile
remained unchanged [18]. Conversely, in endometrial
carcinoma, FST expression is unchanged while FLRG
expression is down-regulated [21]. FLRG was also found
to be down-regulated in ovarian endometriosis, while FST
expression was found to be up-regulated [22]. Collec-
tively, these finds demonstrate a number of differences
between FST and FLRG, further suggesting that they may
not be complete functional homologues.
Finally, a further mechanism to be hypothesized is that
activin may have, similarly to TGFβ, a dual role on cancer
progression. In early phase, TGF-β inhibits growth of can-
cer cells by cytostasis, differentiation and apoptosis. In
later phase, instead, it works to promote cancer progres-
sion and metastasis by several mechanisms including eva-
sion from immunological recognition, production of
growth factors, differentiation into an invasive pheno-
type, metastatic dissemination as much as the establish-
ment and dispersion of metastatic colonies [36,37].
Although whether activins work similar to TGF-β is not
currently known, despite the anti-proliferative actions of
activin, follistatin seems to act as an inhibitor of cancer
metastasis [19].
Conclusion
The current findings suggest a role for FST in breast benign
disease, particularly in FIB, since its expression was
increased in the stromal cells of this benign disease. More-
over, given that both FLRG mRNA and protein are up reg-
ulated in IDC, we conclude that the tumor is the source of
the increased FLRG peptide in this invasive carcinoma. In
addition, since FLRG expression is not altered in DCIS,
but only in IDC, we conclude that FLRG may play an
important role towards malignancy. As activin displays an
anti-proliferative effect in human mammary cells, the
present findings indicate that increased FST and FLRG
expression in breast proliferative diseases might counter-
act the anti-proliferative effects of activin.
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